Branched-Chain Amino Acids

Last Updated: November 14 2022

Branched-chain amino acids (BCAAs) are three essential amino acids that are frequently supplemented because of their role in muscle growth and development. These amino acids are naturally found in dietary protein sources. Studies show that supplementation of BCAAs alone does not increase muscle growth, as all essential amino acids must be present for muscle protein synthesis to occur.

Branched-Chain Amino Acids is most often used for.

Don't miss out on the latest research

Become an Examine Insider for FREE to stay on top of the latest nutrition research, supplement myths, and more


    Sources and Composition


    Sources and Structure

    The three amino acids Leucine, Isoleucine, and Valine are referred to as Branched Chain Amino Acids (BCAAs) as they are the only three amino acids to possess a branched side chain. They are all essential amino acids,[1] and collectively form the largest pool of essential amino acids in the bodily pool (35–40%) and are present in high levels (14–18%) in muscle tissue.[2][3][4] The content of BCAAs in the free amino acid pool is relatively small compared to bodily stores (at around 0.1g/kg or 0.6–1.2mmol/kg of muscle tissue[4]) and the fasted serum concentration of BCAAs tends to be 0.3–0.4mM (which is relatively high compared to all other amino acids, aside from glutamine).[5][6]

    Branched chain amino acids are a group of three essential amino acids that are highly involved in the regulation of muscle mass. They are found in dietary protein.


    Formulations and Variants

    Livact is a brand name for BCAA granules that are used in some cases of cirrhosis, or in clinical settings.[7]





    After ingestion, leucine from food is catalyzed by digestive enzymes into either peptides or free amino acids. Both of these are then taken up from the gut into the liver via their respective transporters. Leucine is taken up into cells via its respective Heterodimeric Amino Acid Transporter[8], most notably the glycoprotein CD98 which also mediates uptake of isoleucine, valine, tryptophan, and tyrosine (branched and aromatic amino acids).[9][10] This inhibition applies to both the blood brain barrier and the intestines.[11]



    Under normal resting unfed states, the enzymes that mediate BCAA catabolism are at about 4-6% activity in the skeletal muscle of rats[12][13] despite being near full capacity in the liver, which is not a main site of catabolism.[12]

    Increased dietary protein (from 8% to 30% of the diet) is known to increase the enzyme that catabolizes BCAAs[14] and this effect is observed with an increase in dietary BCAAs alone (4.8% or 6.2% of the diet of rats)[15] and with exercise.[16] This suggests that BCAA serum concentrations are highly regulated and further suggests an increased dietary need with exercise.[4]

    BCAAs have their bodily stores regulated by the BCAA dehydrogenase complex, which is increased in activity with both exercise and a dietary surplus of BCAAs.

    BCAA catabolism occurs in the cell's mitochondria.[17] The BCAAs undergo reversible conversion to α-keto derivatives (known as branched-chain α-keto acids) via the enzyme branched-chain aminotransferase (BCAT) and then is irreversibly metabolized (oxidative decarboxylation) via the branched-chain α-keto acid dehydrogenase (BCKDH) enzyme,[4] which is thought to be the rate-limiting step of BCAA catabolism.[17][12]

    The rate-limiting step (BCKDH enzyme) is regulated by covalent modification and is activated by BCKDH phosphatase[18] and inactivated by BCKDH kinase[19][20] (dephosphorylation and phosphorylation of E1α, respectively). It is thought that the activity of BCKDH kinase is a determinant of BCKDH activity overall, as they are inversely correlated,[21] but a lack of information on BCKDH phosphatase exists in general.[4]

    Due to the high concentration of BCAT and BCKDH in skeletal muscle and low concentrations in the liver, BCAA catabolism tends to occur in skeletal muscle, [22][13] hence its susceptibility to physical exercise.[16] Most other essential amino acids are catabolized in the liver. There is also a higher concentration of the inhibitory enzyme (BCKDH kinase) in skeletal muscle, [23] which is thought to underlie the low rates of catabolism at rest in skeletal muscle (which is not observed in liver tissue).[12][13]

    BCAA catabolism is controlled by the rate of the rate-limiting enzyme (BCKDH complex). This enzyme is positively (BCKDH phosphatase) and negatively (BCKDH kinase) regulated by other enzymes. They are located in high concentrations in skeletal muscle (hence localized catabolism of BCAAs) and their activity determines BCAA concentrations in a cell.

    When leucine is reversibly metabolized into α-ketoisocaproic acid (KIC) by BCAT using α-ketoglutarate as a cofactor (and producing glutamine in this process) and then irreversibly metabolized into isovaleryl-CoA, Isoleucine is reversibly metabolized into 3-methyl-2-oxopentanoate (KMV) by BCAT using the same cofactor, and KMV is irreversibly metabolized into 2-Methylbutyryl-CoA while valine is metabolized reversibly into 2-ketoisovalerate and then irreversibly into isobutyryl-CoA.[4]

    The BCKDH complex is important in muscle protein synthesis (via leucine preservation, more preservation of this amino acid promotes more signaling from it), which is evidenced by the BCKDH kinase inhibitor clofibric acid[24][25] causing myopathy after prolonged usage.[26][27]

    Other activators of the BCKDH complex (increasing BCAA catabolism) include TNF-α (following injections which raised activity from 22% to 69-86% at 25-50mcg/kg) secondary to decreasing levels of the negative regulator[28] and starvation (by decreasing the negative regulator).[14] Additionally, all BCAA metabolites (the alpha keto acids) are inhibitors of BCKDH kinase and may increase the activity of the complex[24] with α-ketoisocaproate (from leucine) being more potent than the others.[29] HMB at 2mM does not inhibit this kinase.[24]

    Exercise (localized muscle contraction specifically[29]) is well known to activate this complex[14][23] and has been confirmed in human tissue[30] associated with decreasing BCKDH kinase (negative regulator) activity thought to be secondary to altering the levels of bound kinase relative to free kinase.[23]

    Activation of the BCKDH complex (resulting in BCAA catabolism) is associated with myopathy, and cytokines or drugs that increase activity of this complex can increase BCAA catabolism and induce myopathy. The immediate metabolites of BCAAs are known to positively influence enzyme activity and encourage their own catabolism, forming a loop of self-regulation. Exercise is known to increase BCAA oxidation by activating this enzyme complex.





    The central hypothesis of fatigue (which assumes that elevated serotonin concentrations in the brain are associated with induction of fatigue[31][32]) is thought to be related to the antifatigue effects of BCAA supplementation.[33] During exercise, the plasma ratio of aromatic amino acids (applies to both tryptophan and L-tyrosine although the central hypothesis only regards the former) to long chain neutral amino acids (the BCAAs and a few others) is altered in favor of the former[32][34][35] due to BCAAs undergoing oxidation and being destroyed,[16] and due to tryptophan and BCAAs sharing the same transport into the brain.[36][37][38] This act of transportation is the rate-limiting step.[33] Any alteration in the ratio will alter what amino acids transport into the brain. Exercise has been confirmed to increase tryptophan uptake in as little as 30 minutes[39][40] and increasing tryptophan availability via supplementation (without supplemnetal BCAAs) appears to promote fatigue in rats.[41]

    It is thought the increased tryptophan transport into the brain (which produces serotonin via 5-HTP) is a possible causative factor of fatigue, and replenishing oxidized BCAAs to preserve the ratio can attenuate fatigue production.[33]

    Theoretically, tryptophan uptake into the brain increases during exercise. The increased synthesis of serotonin promotes fatigue and sedation. As BCAAs share the same transport into the brain as tryptophan, it is thought loading them prior to exercise is able to hinder tryptophan uptake and serotonin production, thus hindering the onset of fatigue.

    Rats fed a diet containing 3.57-4.76% BCAAs for 6 weeks (control at 1.78%) failed to alter post-exercise serotonin in the hypothalamus as assessed by biopsy[42] but elsewhere valine supplementation (20mg/kg bodyweight) injected immediately prior to running was able to prevent an exercise-induced increase in serotonin production (measured in the hippocampus) at 30 minutes, with mixed efficacy at 90 minutes (serotonin was lower, tryptophan and 5-HIAA were not)[43]

    Adding BCAAs to the rat diet may not prevent serotonin synthesis in the brain, while timed ingestion prior to physical activity (to ensure high levels in serum) has been noted to be effective with isolated valine.



    Although the association between athletes and Amyotrophic Lateral Sclerosis (ALS) is somewhat unreliable and is still up for debate[44] with both positive[45][46] and null[47] evidence, investigation into agents possibly used by these athletes were conducted and BCAAs were suspected.

    The epidemiological link between ALS and athletes is somewhat weak and inconsistent, and even the link between ALS and BCAA supplementation (hypothesized to be more commonly occurring in athletes) is currently unsupported.

    BCAAs have been noted to cause hyperexcitation of neurons (without affecting resting membrane potential) in vitro via mTOR dependent means (blocked by rapamycin) while requiring a sodium channel (blocked by Riluzole). Dose-dependence between 10-300μM was shown with valine, though [48] this did not occur with amino acids without a branched chain.

    As hyperexcitability of neurons is a pathological feature of ALS in humans[49][50] and in the mouse model which mimicks ALS (the G93A model[51][52]), it was thought that this induced hyperexcitability could be a mechanism of action. BCAA-induced hypersensitivity also appeared to be sodium channel dependent, and occurred in mice (B6SJL strain) raised from birth with 2.5% of their diet being BCAAs (1:1:1 ratio).[48]

    It is plausible that BCAAs may increase neuronal excitation via mTOR dependent means, but the in vitro evidence resulted from quite high concentrations, while the mouse model was conducted from birth, which is usually more sensitive to neurological effects but may not accurately represent a non-infant consuming the agent. More research on this topic is needed.


    Interactions with Glucose Metabolism



    Leucine has the potential to promote insulin-induced activation of Akt, but it requires PI3K to be inhibited or suppressed first (and then leucine preserves insulin-induced Akt activation).[53]

    In conditions where insulin is not present, 2mM leucine and (to a lesser degree) its metabolite α-ketoisocaproate appear to promote glucose uptake via PI3K/aPKC (atypical PKC[54]) and independent of mTOR (blocking mTOR does not alter the effects).[55] This study noted stimulation only at 2-2.5mM for 15-45 minutes (resistance developed at 60 minutes) and was comparable in potency to physiological concentrations of basal insulin but underperformed (50% as potent) as 100nM insulin.[55]

    It is possible that leucine can promote glucose uptake in some instances, such as when PI3K is inhibited or when insulin is not present in a cell culture but leucine is (acutely). It appears to have similar mechanisms to isoleucine.

    Leucine is also able to hinder cellular glucose uptake, [56][57][58] which is thought to either be related to activation of mTOR signaling, which naturally suppresses AMPK signaling,[59] (AMPK signaling being one that mediates glucose uptake during periods of low cellular energy and exercise[60][61]) or due to leucine suppressing glucose oxidation, as seen during fasting in muscle cells[56] (a relative preservation of glucose would result in higher cellular concentrations and thus less recompensatory uptake) which is also possibly related to mTOR signaling. Signaling via this pathway is a negative-feedback mechanism of glucose uptake, as it is normally activated by insulin[62] and activation or mTOR eventually hinders IRS-1 signaling[63] (the first substrate after the insulin receptor in the signaling pathway) as mTOR's activation of S6K1 (which induces protein synthesis) also creates serine-threonine kinases, which degrade IRS-1.[64]

    This effect does not appear to be immediate, and cellular culture studies that note glucose uptake also note that prolonged (60 minutes) exposure to leucine eliminates any glucose uptake induced by it,[55] which suggests some form of negative feedback. Additionally, this may explain why the leucine-stimulated increase in glucose uptake is suppressed after 60 minutes.[55]

    The state of hyperaminoacidemia has been noted to induce a transient and reversible state of insulin resistance, thought to be related to leucine content.[57] Elevated plasma BCAAs are observed during obesity and are correlated with insulin resistance.[65][66] Fasting is accompanied by reduced amino acids in serum and increased insulin sensitivity, thought to be due to the amino acid reduction.[58] On a cellular level, this is alleviated with leucine[56] and seen with mixed amino acids in vivo.[58]

    Valine has also shown an inhibitory effect on glucose uptake into muscle cells, but it appears to be more fast acting than leucine (0.3g/kg of either amino acid causing a spike in glucose relative to control at 30 minutes (valine) or 90 minutes with leucine).[67]

    Leucine, secondary to signaling for muscle protein synthesis, can also suppress glucose uptake into a cell after incubation for about an hour, since it may be stimulatory until it suppresses its own actions. Valine has been noted to increase serum glucose more rapidly in the body, suggesting either a faster negative regulation or just no promotion of glucose uptake.

    Isoleucine is known to promote muscular uptake of glucose.[67][68][69] The effects of isoleucine (which can be examined in-depth on its respective page) appear to mostly be independent of the mTOR/AMPK axis, fully dependent on PI3K/PKC, and possibly related to reducing gluconeogenesis of fatty acids (producing less glucose would cause more to need to be taken up from the blood to meet cellular demands).

    Isoleucine is not known to increase glycogen synthesis[67] like leucine is[70] possibly due to glycogen synthesis from amino acids being dependent on mTOR activation,[71][70] which is the result of leucine[59] and not isoleucine.[55]

    Isoleucine counters leucine and can promote glucose uptake into a muscle cell, and although the mechanisms are not fully established, it may be a secondary effect to reducing gluconeogenesis of amino acids. Glycogen synthesis is not upregulated with isoleucine, only uptake and consumption.

    Both valine and isoleucine are glucogenic amino acids and may be converted into glucose in the human body.[72] Leucine is unable to do this and is known as ketogenic, meaning it produces ketone bodies.

    Two of the three BCAAs (not leucine) can be converted into glucose.



    It has been observed that activation of BCAA transaminase occurs during glycogen depletion[73][74] and that the two BCAAs known as isoleucine and valine are capable of being converted to succinyl-CoA (and possibly increase fat oxidation secondary to oxaloacetate;[75] any increase in fat oxidation being able to suppress the rate of glycogen loss during exercise due to comparatively using more lipids).

    Branched chain amino acid supplementation has been noted to preserve hepatic and skeletal muscle glycogen stores after a bout of acute exercise relative to placebo,[15][42] which has been noted in humans subject to submaximal cycling tests with 90mg/kg BCAAs[76] with no inherent effect on glycogen at rest.[15]

    Another study reported 300mg/kg BCAA supplementation (distribution not disclosed) resulting in an increase in blood glucose without altering plasma free fatty acids and lactate in otherwise healthy men subject to glycogen depletion, although a reduction in RER (indicative of more fat oxidation) was noted.[75]


    Blood Glucose

    Possibly related to the general benefits in liver pathology (usually chronic hepatitis),[77][78] increased muscular glucose uptake has been noted in a rat model of liver cirrhosis[79] which has spurred human research. In people with chronic hepatitis C and insulin resistance given BCAA supplementation (12.45g after breakfast and dinner and one dose before sleep) was able to improve insulin sensitivity (Matsuda; no change in HOMA-IR) in a subset of the sample who also benefitted with reduced HbA1c. This did not occur in all participants.[80]

    There appear to be possible benefits to insulin sensitivity and muscular glucose uptake in people with hepatitis, but this effect appears to be unreliable.


    Insulin Sensitivity

    Serum BCAAs appear to be elevated in the fasted state in both obesity[81][82] and when investigating dietary intake of insulin sensitive and resistant people (resistance is also associated with higher fasting BCAA intake[65] and improvement upon weight loss is correlated with normalization of BCAA metabolism[83]). There do not appear to be large dietary differences between the two states.[84][66]

    At least in rats, the increase in serum BCAAs appears to correlate with less activity of the BCKDH enzyme complex in adipose tissue[85] and this enzyme complex appears to be downregulated in the adipose of obese, insulin resistant individuals, relative to their monozygotic twins.[86] Although less researched, it is possible this effect extends to skeletal muscle tissue as well, as a downregulation of some enzymes in the BCAA catabolic chain (methyl-malonate-semialdehyde dehydrogenase and propionyl-CoA carboxylase β) has been noted in humans.[87]

    It is theoretically plausible that excess serum leucine can exacerbate insulin resistance, but the overall relationship is not completely clear[88] since both leucine deprivation[89] and high leucine feeding[90] improve insulin resistant states in rats.

    In insulin resistant states there appears to be a higher circulating level of BCAAs, which is due to the catabolism of BCAAs being impaired. The serum BCAAs are more of a biomarker of insulin resistance than anything (signifying a disturbance of adipose-related insulin sensitivity) and their potentially causative role is not well understood.


    Skeletal Muscle and Physical Performance


    Mechanisms (Skeletal Muscle)

    Leucine is able to activate a protein called 'Target of Rapamycin' (TOR or mTOR in mammals) which stimulates protein synthesis. Inhibiting this protein can prevent the anabolic effects of leucine in rats[91] and humans.[92] mTOR is commonly referred to as the main metabolic target of leucine, and mTOR itself activates the p70 subunit of S6 Kinase (p70S6K in short, ultimately via Ser483[93]) which upregulates ribosomal protein S6 and protein synthesis via signaling through the genome.[94] The eukaryotic binding factor (eIF) is activated and its binding factor (the eukaryotic initiation factor 4E-binding protein; 4E-BP1) is suppressed by mTOR.[95][96][97] Beyond leucine, mTOR can be activated by exercise (muscle contraction, requires a 1-2 hour delay[98][99] related to increasing phosphatidic acid signaling[100] and reducing negative regulators[101]) insulin,[102] and caloric excess (without altering nutrition).[103]

    These effects have been observed in human muscle (assessed via biopsy) following exercise and ingestion of BCAAs. [94] mTOR activation has been noted in human muscle at rest following ingestion of BCAAs[104] and isolated leucine.[105][106] Both 4E-BP1 and p70S6K have also been confirmed with BCAAs[107] and leucine.[108]

    Although Akt (also known as Protein Kinase B or PKB; downstream of the insulin receptor and upstream of mTOR) can activate mTOR directly[109] or indirectly via TSC2,[110][111] which enhances protein translation (via deactivating GSK-3 and enhancing eIF2B signaling[112]) induced by S6K1,[113] this pathway is mostly irrelevant to leucine supplementation as leucine does not influence Akt or GSK-3.[108][94]

    The anabolic effects of leucine are mediated via the mTOR pathway, which responds to dietary leucine to induce muscle protein synthesis. Although mTOR is activated by Akt/PKB signaling (usually from insulin signaling), leucine does not activate this protein and seems to selectively activate mTOR.

    MAFbx (muscle atrophy F-box) and MuRF-1 (muscle RING-finger 1) are two muscle-specific proteins associated with catabolism and atrophy,[114][115] which are positively regulated by FOXO signaling[116] (FOXO signaling is negatively regulated by PI3K/Akt[117]).

    mRNA for MAFbx appears to be reduced by BCAA supplementation (85mg/kg with 45% leucine and 30% valine) following rest (30%) and exerci

    7.^Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Douhara A, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui HCombination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosisMol Med Report.(2012 Feb)
    8.^Reynolds B, Laynes R, Ogmundsdóttir MH, Boyd CA, Goberdhan DCAmino acid transporters and nutrient-sensing mechanisms: new targets for treating insulin-linked disordersBiochem Soc Trans.(2007 Nov)
    9.^Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WMSelective expression of the large neutral amino acid transporter at the blood-brain barrierProc Natl Acad Sci U S A.(1999 Oct 12)
    10.^Pardridge WM, Choi TBNeutral amino acid transport at the human blood-brain barrierFed Proc.(1986 Jun)
    12.^Harris RA, Zhang B, Goodwin GW, Kuntz MJ, Shimomura Y, Rougraff P, Dexter P, Zhao Y, Gibson R, Crabb DWRegulation of the branched-chain alpha-ketoacid dehydrogenase and elucidation of a molecular basis for maple syrup urine diseaseAdv Enzyme Regul.(1990)
    14.^Kobayashi R, Shimomura Y, Murakami T, Nakai N, Otsuka M, Arakawa N, Shimizu K, Harris RAHepatic branched-chain alpha-keto acid dehydrogenase complex in female rats: activation by exercise and starvationJ Nutr Sci Vitaminol (Tokyo).(1999 Jun)
    15.^Shimomura Y, Murakami T, Nakai N, Nagasaki M, Obayashi M, Li Z, Xu M, Sato Y, Kato T, Shimomura N, Fujitsuka N, Tanaka K, Sato MSuppression of glycogen consumption during acute exercise by dietary branched-chain amino acids in ratsJ Nutr Sci Vitaminol (Tokyo).(2000 Apr)
    16.^Howarth KR, Burgomaster KA, Phillips SM, Gibala MJExercise training increases branched-chain oxoacid dehydrogenase kinase content in human skeletal muscleAm J Physiol Regul Integr Comp Physiol.(2007 Sep)
    17.^Harper AE, Miller RH, Block KPBranched-chain amino acid metabolismAnnu Rev Nutr.(1984)
    20.^Shimomura Y, Nanaumi N, Suzuki M, Popov KM, Harris RAPurification and partial characterization of branched-chain alpha-ketoacid dehydrogenase kinase from rat liver and rat heartArch Biochem Biophys.(1990 Dec)
    22.^Suryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SMA molecular model of human branched-chain amino acid metabolismAm J Clin Nutr.(1998 Jul)
    23.^Xu M, Nagasaki M, Obayashi M, Sato Y, Tamura T, Shimomura YMechanism of activation of branched-chain alpha-keto acid dehydrogenase complex by exerciseBiochem Biophys Res Commun.(2001 Sep 28)
    24.^Paxton R, Harris RARegulation of branched-chain alpha-ketoacid dehydrogenase kinaseArch Biochem Biophys.(1984 May 15)
    25.^Kobayashi R, Murakami T, Obayashi M, Nakai N, Jaskiewicz J, Fujiwara Y, Shimomura Y, Harris RAClofibric acid stimulates branched-chain amino acid catabolism by three mechanismsArch Biochem Biophys.(2002 Nov 15)
    26.^Teräväinen H, Larsen A, Hillbom MClofibrate-induced myopathy in the ratActa Neuropathol.(1977 Aug 16)
    28.^Shiraki M, Shimomura Y, Miwa Y, Fukushima H, Murakami T, Tamura T, Tamura N, Moriwaki HActivation of hepatic branched-chain alpha-keto acid dehydrogenase complex by tumor necrosis factor-alpha in ratsBiochem Biophys Res Commun.(2005 Mar 25)
    29.^Shimomura Y, Fujii H, Suzuki M, Fujitsuka N, Naoi M, Sugiyama S, Harris RABranched-chain 2-oxo acid dehydrogenase complex activation by tetanic contractions in rat skeletal muscleBiochim Biophys Acta.(1993 Jul 11)
    30.^Wagenmakers AJ, Brookes JH, Coakley JH, Reilly T, Edwards RHExercise-induced activation of the branched-chain 2-oxo acid dehydrogenase in human muscleEur J Appl Physiol Occup Physiol.(1989)
    31.^Ament W, Verkerke GJExercise and fatigueSports Med.(2009)
    32.^Davis JM, Alderson NL, Welsh RSSerotonin and central nervous system fatigue: nutritional considerationsAm J Clin Nutr.(2000 Aug)
    34.^Blomstrand EAmino acids and central fatigueAmino Acids.(2001)
    37.^Fernstrom JD, Faller DVNeutral amino acids in the brain: changes in response to food ingestionJ Neurochem.(1978 Jun)
    39.^Blomstrand E, Møller K, Secher NH, Nybo LEffect of carbohydrate ingestion on brain exchange of amino acids during sustained exercise in human subjectsActa Physiol Scand.(2005 Nov)
    40.^Nybo L, Nielsen B, Blomstrand E, Moller K, Secher NNeurohumoral responses during prolonged exercise in humansJ Appl Physiol.(2003 Sep)
    41.^Meeusen R, Thorré K, Chaouloff F, Sarre S, De Meirleir K, Ebinger G, Michotte YEffects of tryptophan and/or acute running on extracellular 5-HT and 5-HIAA levels in the hippocampus of food-deprived ratsBrain Res.(1996 Nov 18)
    42.^Falavigna G, Alves de Araújo J Jr, Rogero MM, Pires IS, Pedrosa RG, Martins E Jr, Alves de Castro I, Tirapegui JEffects of diets supplemented with branched-chain amino acids on the performance and fatigue mechanisms of rats submitted to prolonged physical exerciseNutrients.(2012 Nov 16)
    43.^Gomez-Merino D, Béquet F, Berthelot M, Riverain S, Chennaoui M, Guezennec CYEvidence that the branched-chain amino acid L-valine prevents exercise-induced release of 5-HT in rat hippocampusInt J Sports Med.(2001 Jul)
    47.^Valenti M, Pontieri FE, Conti F, Altobelli E, Manzoni T, Frati LAmyotrophic lateral sclerosis and sports: a case-control studyEur J Neurol.(2005 Mar)
    48.^Carunchio I, Curcio L, Pieri M, Pica F, Caioli S, Viscomi MT, Molinari M, Canu N, Bernardi G, Zona CIncreased levels of p70S6 phosphorylation in the G93A mouse model of Amyotrophic Lateral Sclerosis and in valine-exposed cortical neurons in cultureExp Neurol.(2010 Nov)
    50.^Zanette G, Tamburin S, Manganotti P, Refatti N, Forgione A, Rizzuto NChanges in motor cortex inhibition over time in patients with amyotrophic lateral sclerosisJ Neurol.(2002 Dec)
    52.^van Zundert B, Peuscher MH, Hynynen M, Chen A, Neve RL, Brown RH Jr, Constantine-Paton M, Bellingham MCNeonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosisJ Neurosci.(2008 Oct 22)
    54.^Uberall F, Hellbert K, Kampfer S, Maly K, Villunger A, Spitaler M, Mwanjewe J, Baier-Bitterlich G, Baier G, Grunicke HHEvidence that atypical protein kinase C-lambda and atypical protein kinase C-zeta participate in Ras-mediated reorganization of the F-actin cytoskeletonJ Cell Biol.(1999 Feb 8)
    55.^Nishitani S, Matsumura T, Fujitani S, Sonaka I, Miura Y, Yagasaki KLeucine promotes glucose uptake in skeletal muscles of ratsBiochem Biophys Res Commun.(2002 Dec 20)
    57.^Tessari P, Inchiostro S, Biolo G, Duner E, Nosadini R, Tiengo A, Crepaldi GHyperaminoacidaemia reduces insulin-mediated glucose disposal in healthy manDiabetologia.(1985 Nov)
    61.^O'Neill HMAMPK and Exercise: Glucose Uptake and Insulin SensitivityDiabetes Metab J.(2013 Feb)
    64.^Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, Olefsky JM, Kobayashi MA rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1Mol Endocrinol.(2000 Jun)
    65.^Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy WS Jr, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LPA branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistanceCell Metab.(2009 Apr)
    66.^Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten REMetabolite profiles and the risk of developing diabetesNat Med.(2011 Apr)
    67.^Doi M, Yamaoka I, Fukunaga T, Nakayama MIsoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubesBiochem Biophys Res Commun.(2003 Dec 26)
    71.^Armstrong JL, Bonavaud SM, Toole BJ, Yeaman SJRegulation of glycogen synthesis by amino acids in cultured human muscle cellsJ Biol Chem.(2001 Jan 12)
    72.^Letto J, Brosnan ME, Brosnan JTValine metabolism. Gluconeogenesis from 3-hydroxyisobutyrateBiochem J.(1986 Dec 15)
    73.^van Hall G, MacLean DA, Saltin B, Wagenmakers AJMechanisms of activation of muscle branched-chain alpha-keto acid dehydrogenase during exercise in manJ Physiol.(1996 Aug 1)
    74.^Gibala MJ, Young ME, Taegtmeyer HAnaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscleActa Physiol Scand.(2000 Apr)
    75.^Gualano AB, Bozza T, Lopes De Campos P, Roschel H, Dos Santos Costa A, Luiz Marquezi M, Benatti F, Herbert Lancha Junior ABranched-chain amino acids supplementation enhances exercise capacity and lipid oxidation during endurance exercise after muscle glycogen depletionJ Sports Med Phys Fitness.(2011 Mar)
    76.^Blomstrand E, Hassmén P, Ek S, Ekblom B, Newsholme EAInfluence of ingesting a solution of branched-chain amino acids on perceived exertion during exerciseActa Physiol Scand.(1997 Jan)
    77.^Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R; Italian BCAA Study GroupNutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trialGastroenterology.(2003 Jun)
    78.^Kawamura-Yasui N, Kaito M, Nakagawa N, Fujita N, Ikoma J, Gabazza EC, Watanabe S, Adachi YEvaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver diseaseJ Clin Lab Anal.(1999)
    79.^Nishitani S, Takehana K, Fujitani S, Sonaka IBranched-chain amino acids improve glucose metabolism in rats with liver cirrhosisAm J Physiol Gastrointest Liver Physiol.(2005 Jun)
    80.^Takeshita Y, Takamura T, Kita Y, Ando H, Ueda T, Kato K, Misu H, Sunagozaka H, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko SBeneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance: implications for type 2 diabetesMetabolism.(2012 Oct)
    81.^Felig P, Marliss E, Cahill GF JrPlasma amino acid levels and insulin secretion in obesityN Engl J Med.(1969 Oct 9)
    83.^Shah SH, Crosslin DR, Haynes CS, Nelson S, Turer CB, Stevens RD, Muehlbauer MJ, Wenner BR, Bain JR, Laferrère B, Gorroochurn P, Teixeira J, Brantley PJ, Stevens VJ, Hollis JF, Appel LJ, Lien LF, Batch B, Newgard CB, Svetkey LPBranched-chain amino acid levels are associated with improvement in insulin resistance with weight lossDiabetologia.(2012 Feb)
    84.^Tai ES, Tan ML, Stevens RD, Low YL, Muehlbauer MJ, Goh DL, Ilkayeva OR, Wenner BR, Bain JR, Lee JJ, Lim SC, Khoo CM, Shah SH, Newgard CBInsulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian menDiabetologia.(2010 Apr)
    85.^She P, Reid TM, Bronson SK, Vary TC, Hajnal A, Lynch CJ, Hutson SMDisruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycleCell Metab.(2007 Sep)
    86.^Pietiläinen KH, Naukkarinen J, Rissanen A, Saharinen J, Ellonen P, Keränen H, Suomalainen A, Götz A, Suortti T, Yki-Järvinen H, Oresic M, Kaprio J, Peltonen LGlobal transcript profiles of fat in monozygotic twins discordant for BMI: pathways behind acquired obesityPLoS Med.(2008 Mar 11)
    88.^Lu J, Xie G, Jia W, Jia WInsulin resistance and the metabolism of branched-chain amino acidsFront Med.(2013 Mar)
    89.^Xiao F, Huang Z, Li H, Yu J, Wang C, Chen S, Meng Q, Cheng Y, Gao X, Li J, Liu Y, Guo FLeucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathwaysDiabetes.(2011 Mar)
    91.^Anthony JC, Yoshizawa F, Anthony TG, Vary TC, Jefferson LS, Kimball SRLeucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathwayJ Nutr.(2000 Oct)
    92.^Drummond MJ, Fry CS, Glynn EL, Dreyer HC, Dhanani S, Timmerman KL, Volpi E, Rasmussen BBRapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesisJ Physiol.(2009 Apr 1)
    94.^Blomstrand E, Eliasson J, Karlsson HK, Köhnke RBranched-chain amino acids activate key enzymes in protein synthesis after physical exerciseJ Nutr.(2006 Jan)
    95.^Wang X, Proud CGThe mTOR pathway in the control of protein synthesisPhysiology (Bethesda).(2006 Oct)
    96.^Proud CGmTOR-mediated regulation of translation factors by amino acidsBiochem Biophys Res Commun.(2004 Jan 9)
    102.^Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DHInsulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40Nat Cell Biol.(2007 Mar)
    103.^Elmadhun NY, Lassaletta AD, Chu LM, Sellke FWMetformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndromeJ Thorac Cardiovasc Surg.(2013 Jan)
    106.^Alvestrand A, Hagenfeldt L, Merli M, Oureshi A, Eriksson LSInfluence of leucine infusion on intracellular amino acids in humansEur J Clin Invest.(1990 Jun)
    108.^Greiwe JS, Kwon G, McDaniel ML, Semenkovich CFLeucine and insulin activate p70 S6 kinase through different pathways in human skeletal muscleAm J Physiol Endocrinol Metab.(2001 Sep)
    110.^Inoki K, Li Y, Zhu T, Wu J, Guan KLTSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signallingNat Cell Biol.(2002 Sep)
    113.^Browne GJ, Proud CGRegulation of peptide-chain elongation in mammalian cellsEur J Biochem.(2002 Nov)
    115.^Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJIdentification of ubiquitin ligases required for skeletal muscle atrophyScience.(2001 Nov 23)
    116.^Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg ALFoxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophyCell.(2004 Apr 30)
    117.^Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJThe IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factorsMol Cell.(2004 May 7)